Genomic tumor evolution dictates human medulloblastoma progression.

Area of Science:

• Oncology
• Genomics
• Pediatric Neuro-oncology

Background:

• Medulloblastoma (MB) is the most common pediatric brain tumor, with Group 3 and Group 4 subgroups being poorly characterized.
• High inter- and intratumoral heterogeneity in MB hinders the identification of therapeutic targets.
• Group 3 MB has a poor prognosis (~50% survival), while Group 4 is the most prevalent.

Purpose of the Study:

• To characterize cell-cell interactions, tumor progression, and evolution in medulloblastoma.
• To identify potential therapeutic targets for Group 3 and Group 4 medulloblastoma.
• To unravel the tumor evolutionary trajectory linked to copy number variations (CNVs).

Main Methods:

• Single-cell RNA sequencing data from 14 MB patients and public datasets.
• Ligand-receptor analysis using CellChat.
• Copy-number variation (CNV) detection and RNA velocity analysis.

Main Results:

• Medulloblastoma tumor cells exhibit a temporal progression from low to high CNV levels.
• Early and late molecular markers were identified for sonic-hedgehog (SHH), Group 3, and Group 4 MBs.
• SOX4 upregulation was identified as a significant event in later tumor clones of Group 3 and Group 4 MBs.

Conclusions:

• Medulloblastoma displays significant tumor heterogeneity and complex evolutionary dynamics.
• SOX4 is a potential therapeutic target for Group 3 and Group 4 medulloblastoma.
• Understanding tumor evolution provides insights into MB progression and potential treatment strategies.